Advances in therapy
-
Advances in therapy · Jul 2012
Meta AnalysisCost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Biologic therapies have demonstrated efficacy and safety in several chronic systemic disorders. The authors indirectly compared response rates and costs per responder associated with biologic treatments for moderate-to-severe Crohn's disease (CD), psoriasis (Ps), and/or rheumatoid arthritis (RA). ⋯ Meta-analyses of clinical trials found considerable variation in cost-effectiveness of biologic therapies for CD, Ps, and RA. These results may help determine biologic utilization in these chronic diseases.